A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

The U.S. government will pay the vaccine maker Moderna $176 million to accelerate development of a pandemic influenza vaccine that could be used to treat bird flu in people, as concern grows about ...

The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

To that end, HHS has granted Moderna $590 million to help accelerate the development of a bird flu vaccine. The agency announced its backing of the Massachusetts-based pharmaceutical firm about 72 ...

The S&P 500 fell 1.1% on Tuesday, Jan. 7, as U.S. manufacturing data reinvigorated concerns about inflation and the interest rate outlook.

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.

The current public-health risk is low, but the CDC is working with states to monitor people with animal exposure.

Moderna stock (MRNA) fell over 9% on Wednesday, forfeiting most of its gains from Tuesday's session during a volatile week for the stock seen after the first reported bird flu death in the US ...

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...